# Effect of Secukinumab on Cardiorenal Outcomes in Patients With Cardiorenal Metabolic Syndrome and Atherosclerotic Cardiovascular Disease

> **NCT07704190** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Peking University Third Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Cardiorenal Metabolic Syndrome
- Atherosclerotic Cardiovascular Disease
- Chronic Kidney Disease
- Coronary Artery Disease
- Hypertension
- Type 2 Diabetes Mellitus
- Peripheral Arterial Disease
- Carotid Artery Stenosis

## Interventions

- **BIOLOGICAL:** Secukinumab (75 mg)
- **OTHER:** Standard Medical Therapy

## Key facts

- **NCT ID:** NCT07704190
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-15
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07704190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07704190, "Effect of Secukinumab on Cardiorenal Outcomes in Patients With Cardiorenal Metabolic Syndrome and Atherosclerotic Cardiovascular Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07704190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*